甲状腺癌与干扰素-γ、白介素-6关系的研究进展

doi:10.11904/j.issn.1002-3070.2017.01.019

Abstract

Abstract: Thyroid cancer is the most common malignancy in the endocrine system.In recent years,the incidence of thyroid cancer has increased year by year,which sparked people's attention.With the development of thyroid cancer research,it is found that cytokines play a key role in the occurrence and development of tumor.At present,the cause of thyroid carcinoma and mechanism is not yet entirely clear,however,the occurrence of thyroid cancer is possiblely associated with the body regulating cellular immune dysfunction.Cytokines play an important role in the whole process,in which the relationship between cytokines IFN-γ,IL-6 and thyroid carcinoma is closely related.

Key words: Thyroid carcinoma, Interferon-γ, Interleukin-6

CLC Number:

R736.1

JIAO Yuying, FU Peng. Research progress in relationships between thyroid carcinoma and interferon-γ and interleukin-6[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 88-92.

References

1 Pellegriti G,Frasca F,Regalbuto C,et al.Wordwide increasing incidence of thyroid cancer:update on epidemiology and risk factors[J].Cancer Epidemiol,2013,2013(1):965212-965222.
2 Muller-Hubenthal B,Azemar M,Lorenzen D,et al.Tumour biology:tumour-associated inflammation versus antitumor immunity[J].Anticancer Res,2009,29(11):4795-4805.
3 Cunha LL,Tincani Aj,Assumpcao LV,et al.Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer[J].Clinics(Sao Paulo),2011,66(7):1203-1208.
4 Lumashi F,Basso SM,Orlando R.Cytokines,thyroid diseases and thyroid cancer[J].Cytokine,2010,50(3):229-233.
5 Bodelon C,Polley MY,Kemp TJ,et al.Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer[J].Ann Oncol,2013,24(8):2073-2079.
6 Mazumder A,Rosenberg SA.Successful immunotherapy of nature killer resistant estalished pubmonary melanoma metastases by the intravenous adoptive transfer of sysgnic lymphocytes activated in vitro by interlenkin 2[J].J Exp Med,1984,159(2):495-507.
7 Zivancevic-Simonovic S,Mihaljevic O,Majstorovic I,et al.Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis[J].Cancer Immunol Immunother,2015,64(8):1011-1019.
8 Simonovic SZ,Mihaljevic O,Majstorovic I,et al.Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer:elevated Th2/Th9 production before and reduced Th2 cytokine production after radioactive iodine therapy[J].Cancer Immunol Immunother,2015,64(1):75-82.
9 Kobawala TP,Trivedi TI,Gajjar KK,et al.Significance of interleukin-6 in papillary thyroid carcinoma[J].J Thyroid Res,2016,2016(6):1-12.
10 Miyata T,Honma R,Sato A,et al.Effect of rCaIFN-γ pretreatment on propofol-isoflurane suppression of NK cytotoxic activity in the peripheral blood of dogs[J].Res Vet Sci,2015,98:25-29.
11 Liu J,Duan Y,Cheng X,et al.IL-17 is associated with poor prognosis and promotes via stimulating VEGF production of cancer cells in colorectal carcinoma[J].Biochem Biophys Res Commun,2011,407(2):348-354.
12 Lv N,Gao Y,Guan H,et al.Inflammatory mediators,tumor necrosis factor-α and interferon-γ,induce EMT in human PTC cell lines[J].Oncol Lett,2015,10(4):2591-2597.
13 Hossain MS,Bhimani C,Zhengjia C,et al.Profiling counter-regulatory and cytotoxic immune pathways with cellular biomarkers in thyroid cancer patients[J].Cancer Res,2011,71(8):5525-5535.
14 Kura Y,De Velasco MA,Kobayashi Y,et al.Interleukin-6(IL-6)as a therapeutic target in prostate cancer[J].Cancer Res,2013,73(8):1226-1238.
15 Qi YF,Huang YX,Wang HY,et al.Elucidating the crosstalk mechanism between IFN-gamma and IL-6 via mathematical modelling[J].BMC Bioinformatics,2013,14(1):41-62.
16 Croker BA,Kiu H,Nicholson SE.SOCS regulation of the JAK/STAT signalling pathway[J].Semin Cell Dev Bio,2008,19(4):414-422.
17 Francipane MG,Eterno V,Spina V,et al.Suppressor of cytokine signaling 3 sensitizes anaplastic thyroid cancer to standard chemotherapy[J].Cancer Res,2009,69(15):6141-6148.
18 Croker BA,Krebs DL,Zhang JG,et al.SOCS3 negatively regulates IL-6 signaling in vivo[J].Nat Immunol,2003,4(6):540-545.
19 Mali SB.Review of STAT3(Signal Transducers and Activators of Transcription)in head and neck cancer[J].Oral Oncol,2015,51(6):565-569.
20 Fan TF,Bu LL,Wang WM,et al.Tumor growth suppression by inhibiting both autophagy and STAT3 signaling in HNSCC[J].Oncotarget,2015,6(41):43581-43593.
21 Kolosenko I,Grander D,Tamm KP.IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma[J].Curr Med Chem,2014,21(26):3042-3047.
22 Pencik J,Wiebringhaus R,Susani M,et al.IL-6/STAT3/ARF:the guardians of senescence,cancer progression and metastasis in prostate cancer[J].Swiss Med Wkly,2015,145(4):14215-14225.
23 Lumachi F,Basso SM,Orlando R.Cytokines,thyroid diseases and thyroid cancer[J].Cytokine,2010,50(3):229-233.
24 Zhang J,Gill A,Atmore B,et al.Upregulation of the signal transducers and activators of transcription 3(STAT3)pathway in lymphatic metastases of papillary thyroid cancer[J].Int J Clin Exp Pathol,2011,4(4):356-362.
25 McFarland BC,Gray GK,Nozell SE,et al.Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells[J].Mol Cancer Res,2013,11(5):494-505.
26 Grabner B,Schramek D,Mueller KM,et al.Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis[J].Nat Commun,2015,6(5):6285-6299.
27 Couto JP,Daly L,Almeida A,et al.STAT3 negatively regulates thyroid tumorigenesis[J].Proc Natl Acad Sci USA,2012,109(35):2361-2370.
28 Bluyssen HA,Rastmanesh MM,Tilburgs C,et al.IFN gamma-dependent SOCS3 expression inhibits IL-6-induced STAT3 phosphorylation and differentially affects IL-6 mediated transcriptional responses in endothelial cells[J].Am J of Physiol Cell Physiol,2010,299(2):354-362.
29 Costa-Pereira AP,Tininini S,Strobl B,et al.Mutational switch of an IL-6 response to an interferon-gamma-like response[J].Proc Natl Acad Sci USA,2002,99(12):8043-8047.
30 Su Z,Sun Y,Zhu H,et al.Th17 cell expansion in gastric cancer may contribute to cancer development and metastasis[J].Immunol Re,2014,58(1):118-124.
31 Guarino V,Castellone MD,Avilla E,et al.Thyroid cancer and inflammation[J].Mol Cell Endocrinol,2010,321(1):94-102.
32 Koperek O,Asari R,Niederle B,et al.Desmoplastic stromal reaction in papillary thyroid microcarcinoma[J].Histopathology,2011,58(6):919-924.
33 Provatopoulou X,Georgiadou D,Sergentanis TN,et al.Interleukins as markers of inflammation in malignant and benign thyroid disease[J].Inflamm Res,2014,63(8):667-674.
34 Toral P,Trupti I,Kinjal K,et al.Significance of Interleukin-6 in papillary thyroid carcinoma[J].J Thyroid Res,2016,2016(6):1-12.
35 Cil E,Kumral A,Vural P,et al.Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer[J].Mol Biol Rep,2014,41(5):3091-3097.
36 Lun Y,Wu X,Xia Q,et al.Hashimoto's thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis[J].Otolaryngol Head Neck Surg,2013,148(3):396-402.
37 Schaper F,Rose-John S.Interleukin-6:Biology,signaling and strategies of blockade[J].Cytokine Growth Factor Rev,2015,26(5):475-487.
38 Atsumi T,Singh R,Sabharwal L,et al.Inflammation amplifier,a new paradigm in cancer biology[J].Cancer Res,2014,74(1):8-14.
39 Guarino V,Castellone MD,Avilla E,et al.Thyroid cancer and inflammation[J].Mol Cell Endocrinol,2010,321(1):94-102.
40 Engelmann D,Koczan D,Ricken P,et al.Transcriptome analysis in mouse tumors induced by RetMEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance[J].Endocr Relat Cancer,2009,16(1):211-224.
41 Knauf JA,Sartor MA,Medvedovic M,et al.Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGF-β signaling[J].Oncogene,2011,30(30):3153-3162.

[1]	LI Shiliang ,XU Lei ,SHAO Guoan ,SUN Fenfen ,SUN Linyong ,XUE Jun. Expression and clinical significance of small fragments of P28 and P43 in papillary thyroid carcinoma after TRa1 gene transcription [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 294-298.
[2]	FENG Zhuoying, LU Yao, SU Yanxin, DU Yang. Logistic regression model for ultrasonic evaluation of thyroid nodule benign and malignancy and lymphatic metastasis [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 385-389.
[3]	DING Zhaoming, CHEN Zhuo, CHEN Lili. The relationship between thyroid carcinoma and psychosocial risk factors [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(5): 414-419.
[4]	WANG Di,HE Yuehan,WANG Xinghua,YU Hongbo,WANG Yujun,CUI Yali. Clinical observation of ¹³¹I in treatment of adolescents with differentiated thyroid carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 193-196.
[5]	TIANG Songyu,QIN Huadong,SHI Tiefeng,LIU Yao,SUN Yu. The correlation between breast cancer and thyroid carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2011, 25(4): 333-335.
[6]	SUN Jie, GUAN Haixia, WANG Liyao, WANG Cuifang. Expression of Twist and E-cadherin in papillary thyroid carcinoma and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2009, 23(4): 342-345.

Research progress in relationships between thyroid carcinoma and interferon-γ and interleukin-6

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 6

Recommended Articles

Metrics

Comments